iosBio’s vaccine development pipeline
OmniFlu™ is the world’s first omni-valent influenza vaccine capable of delivering up to 15 strains in a single dose. Current products can only deliver 3 or 4. This can reduce the potential for strain selection mismatches (which in recent influenza seasons have been as high as 50%). This broadens the immunity of patients thereby saving lives, reducing hospitalizations.
OmniFlu™ is now in development and could represent a paradigm shift in the way that society deals with the seasonal threat of influenza. The market for influenza is forecast to grow to $4.3bn by 2025 and currently is dominated by only four suppliers
OraPro-Zika is an oral vaccine against the Zika virus, by inducing immunity against multiple antigens on the Zika virus it provides broader immunity. This broader immunity has been shown in nonclinical studies to be as effective as natural immunity gained by previous exposure to the whole virus. The oral capsules are thermally stable and do not require a cold-chain for worldwide distribution.
iosBio’s VZV vaccine uses the OKA vaccine strain. It has highly enhanced thermal stability at room temperature giving several hours with minimal loss of titre and suffers lower losses on lyophilisation, according to published results. Once dried, the virus demonstrates enhanced stability with minimal losses observed over at least 7 weeks at 25°C. Finally, upon reconstitution with iosBio excipient mixes the virus remains in a state of elevated stability.
Butyrylcholinesterase (BuChE) is a naturally occurring protein found in minute quantities in human blood (2 mg/liter). BuChE functions as a natural bio-scavenger, like a sponge, to absorb and degrade poisons (e.g. nerve agents) before they cause neurological damage. Uniquely, iosBio can deliver reproducible doses of infectious non-replicating viral vectors to the luminal surface of the intestinal mucosa. Once the epithelial lining cells are infected they can produce proteins which can accumulate in the blood. The proteins can be expressed for several days but, if necessary, further doses of vector can be administered to extend the period over which the cells express the protein of interest.